Famciclovir
Brand names: Famvir
Famciclovir is an oral antiviral prodrug used to treat herpes zoster (shingles) and herpes simplex infections, including genital herpes.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is converted to penciclovir, which is phosphorylated by viral thymidine kinase and then host kinases to a triphosphate that inhibits viral DNA polymerase and DNA replication.
Prescribing in practice
- Treatment of herpes zoster is most effective when started as early as possible after rash onset, so prompt initiation is the priority.
- Dose adjustment is required in renal impairment because penciclovir is renally cleared.
- It does not eradicate latent virus, so recurrences can still occur after treatment.
Monitoring
Routine laboratory monitoring is not usually required, but assess renal function in those at risk and review clinical response.
Counselling the patient
- Start treatment as soon as possible after symptoms or rash begin.
- Maintain good fluid intake, particularly if you have kidney problems.
- This treats outbreaks but does not cure the underlying infection, which may recur.
Evidence & guidelines
Famciclovir is an established oral option for herpes zoster and herpes simplex in UK clinical guidance, comparable to other guanine-analogue antivirals.
Reference: NICE CKS; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023